Published in Ophthalmology on May 01, 2001
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology (2011) 2.00
Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol (2014) 1.99
Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol (2006) 1.49
Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol (2005) 1.23
Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol (2006) 1.21
Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol (2008) 1.15
Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes. Br J Ophthalmol (2005) 1.13
Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol (2007) 1.12
Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol (2003) 1.06
Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization. Eye (Lond) (2013) 1.03
Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol (2014) 1.02
Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks. Graefes Arch Clin Exp Ophthalmol (2005) 1.02
Photodynamic therapy in macular diseases of asian populations: when East meets West. Jpn J Ophthalmol (2006) 1.01
Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy. Int J Ophthalmol (2013) 1.00
Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol (2003) 0.98
Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol (2010) 0.97
Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol (2003) 0.96
Low-fluence-rate photodynamic therapy to treat subfoveal choroidal neovascularization in pathological myopia. A study of efficacy and safety. Graefes Arch Clin Exp Ophthalmol (2010) 0.96
Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol (2009) 0.96
Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol (2004) 0.93
Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol (2006) 0.90
Long-term control of choroidal neovascularization in quiescent congenital toxoplasma retinochoroiditis with photodynamic therapy: 4-year results. Int Ophthalmol (2009) 0.90
The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int Ophthalmol (2001) 0.89
Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia. Br J Ophthalmol (2003) 0.89
Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) (2013) 0.89
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clin Ophthalmol (2013) 0.88
Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol (2007) 0.87
Recent trends in the management of maculopathy secondary to pathological myopia. Graefes Arch Clin Exp Ophthalmol (2011) 0.87
Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol (2011) 0.86
Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol (2006) 0.85
Choroidal neovascularization in highly myopic eyes after cataract surgery. Jpn J Ophthalmol (2006) 0.85
Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol (2009) 0.85
Histological findings of a surgically excised myopic choroidal neovascular membrane after photodynamic therapy. A case report. Graefes Arch Clin Exp Ophthalmol (2004) 0.85
Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy. Br J Ophthalmol (2003) 0.84
[Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results]. Ophthalmologe (2004) 0.84
Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol (2004) 0.83
Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy. Graefes Arch Clin Exp Ophthalmol (2007) 0.83
Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol (2003) 0.82
Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol (2004) 0.82
Novel automated screening of age-related macular degeneration. Jpn J Ophthalmol (2012) 0.81
Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of oman. Oman Med J (2008) 0.81
Choroidal neovascularization following laser in situ keratomileusis for high myopia: a case series. Int Ophthalmol (2012) 0.81
Potential bias in ophthalmic pharmaceutical clinical trials. Clin Ophthalmol (2008) 0.81
Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol (2003) 0.81
Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefes Arch Clin Exp Ophthalmol (2005) 0.81
Photodynamic therapy: current role in the treatment of chorioretinal conditions. Eye (Lond) (2016) 0.80
Neuroprotective response after photodynamic therapy: role of vascular endothelial growth factor. J Neuroinflammation (2011) 0.80
Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration. Clin Ophthalmol (2013) 0.80
The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization. J Ocul Pharmacol Ther (2011) 0.80
Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization. Retina (2011) 0.80
The effect of digital measurement software on photodynamic therapy. Graefes Arch Clin Exp Ophthalmol (2005) 0.79
Photodynamic therapy for age-related macular degeneration in Japanese patients: results after one year. Jpn J Ophthalmol (2007) 0.79
Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol (2010) 0.79
Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population. Graefes Arch Clin Exp Ophthalmol (2011) 0.79
Age-related macular degeneration: beyond anti-angiogenesis. Mol Vis (2014) 0.79
Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br J Ophthalmol (2007) 0.79
Current and emerging treatment options for myopic choroidal neovascularization. Clin Ophthalmol (2015) 0.78
Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. Drugs Aging (2014) 0.78
Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration. Int J Mol Sci (2015) 0.78
Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews? Ophthalmology (2016) 0.77
Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology (2002) 0.77
Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. Drug Des Devel Ther (2015) 0.77
Photodynamic therapy for choroidal neovascularization. The Jules Gonin Lecture, Montreux, Switzerland, 1 September 2002. Graefes Arch Clin Exp Ophthalmol (2003) 0.77
Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy. Korean J Ophthalmol (2006) 0.77
Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study. Int Ophthalmol (2013) 0.77
Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration. Br J Ophthalmol (2003) 0.77
Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol (2014) 0.77
The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients. Br J Ophthalmol (2007) 0.76
Outcome of photodynamic therapy in choroidal neovascularization due to pathologic myopia and related factors. Int Ophthalmol (2012) 0.76
[Photodynamic therapy for severe myopia]. Ophthalmologe (2004) 0.75
[Transpupillary thermotherapy for subfoveal choroidal neovascularization. A 9-month follow-up]. Ophthalmologe (2004) 0.75
Aqueous Levels of Pigment Epithelium-Derived Factor and Macular Choroidal Thickness in High Myopia. J Ophthalmol (2015) 0.75
Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study. Clin Ophthalmol (2016) 0.75
Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Korean J Ophthalmol (2007) 0.75
Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study. Int J Ophthalmol (2014) 0.75
Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc (2015) 0.75
Is reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization? Clin Ophthalmol (2008) 0.75
A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation. Saudi J Ophthalmol (2014) 0.75
Optical coherence tomography to monitor photodynamic therapy in pathological myopia. Br J Ophthalmol (2006) 0.75
Photodynamic therapy of symptomatic choroidal nevi. Middle East Afr J Ophthalmol (2011) 0.75
Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study. BMC Ophthalmol (2014) 0.75
Intravitreal aflibercept for myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol (2016) 0.75
[Photodynamic therapy with verteporfin for uveal melanoma]. Ophthalmologe (2005) 0.75
Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
[Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia]. Ophthalmologe (2009) 0.75
Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization. Clin Ophthalmol (2017) 0.75
Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol (2016) 0.75
Clinical characteristics and visual outcome of macular hemorrhage in pathological myopia with or without choroidal neovascularization. Taiwan J Ophthalmol (2016) 0.75
Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy. Graefes Arch Clin Exp Ophthalmol (2006) 0.75
Clinical characteristics and antivascular endothelial growth factor effect of choroidal neovascularization in younger patients in Taiwan. Taiwan J Ophthalmol (2015) 0.75
Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study. Jpn J Ophthalmol (2017) 0.75
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol (2003) 2.30
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol (2004) 1.19